Sanguinarine chloride

CAS No. 5578-73-4

Sanguinarine chloride( —— )

Catalog No. M15029 CAS No. 5578-73-4

Sanguinarine-containing mouthwashes are marketed as anti-plaque and anti-malodor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 49 In Stock
5MG 77 In Stock
10MG 133 In Stock
25MG 240 In Stock
100MG Get Quote In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Sanguinarine chloride
  • Note
    Research use only, not for human use.
  • Brief Description
    Sanguinarine-containing mouthwashes are marketed as anti-plaque and anti-malodor.
  • Description
    Sanguinarine-containing mouthwashes are marketed as anti-plaque and anti-malodor.(In Vitro):Sanguinarine (SANG)-induced apoptosis is associated with the activation of JNK and NF-κB signal pathways.To determine the effects of Sanguinarine on cell viability, 22B-cFluc cells are stimulated with different concentrations of Sanguinarine for 24 h, and then a CKK-8 assay is performed. The treatment with Sanguinarine decreases the proliferation of 22B cells in a dose-dependent manner. Meanwhile, the cytosolic extracts of 22B-cFluc cells treated with different dose of Sanguinarine are measured to detect cellular caspase-3 activity using Ac-DEVD-pNA, which is a validated caspase-3 substrate. The absorbance at 450 nm increases in a dose-dependent manner, indicating increased caspase-3 activity stimulated by Sanguinarine. (In Vivo):To evaluate the apoptosis induced by Sanguinarine (SANG) in vivo, 22B-cFluc cells are inoculated subcutaneously into one flank of nude mice and xenograft models are allowed to establish. Mice are treated intravenously with 10 mg/kg of Sanguinarine. At 24, 48 and 72 h after treatment, bioluminescent imaging is performed after i.p. injection of mice with 150 mg/kg of D-luciferin substrate. Sanguinarine treatment induces an obvious increase of luminescent signal as early as 48 h after initial treatment. A sustained bioluminescent imaging (BLI) intensity increased is observed throughout the course of experiment. At 72 h after treatment, the tumors are collected and subjected to TUNEL staining for evaluating apoptosis. Compared with the control tumors, the group treated with Sanguinarine exhibits significantly more cell apoptosis, indicated by the increased green signals from the sporadic apoptotic cells.
  • In Vitro
    Sanguinarine (SANG)-induced apoptosis is associated with the activation of JNK and NF-κB signal pathways.To determine the effects of Sanguinarine on cell viability, 22B-cFluc cells are stimulated with different concentrations of Sanguinarine for 24 h, and then a CKK-8 assay is performed. The treatment with Sanguinarine decreases the proliferation of 22B cells in a dose-dependent manner. Meanwhile, the cytosolic extracts of 22B-cFluc cells treated with different dose of Sanguinarine are measured to detect cellular caspase-3 activity using Ac-DEVD-pNA, which is a validated caspase-3 substrate. The absorbance at 450 nm increases in a dose-dependent manner, indicating increased caspase-3 activity stimulated by Sanguinarine.
  • In Vivo
    To evaluate the apoptosis induced by Sanguinarine (SANG) in vivo, 22B-cFluc cells are inoculated subcutaneously into one flank of nude mice and xenograft models are allowed to establish. Mice are treated intravenously with 10 mg/kg of Sanguinarine. At 24, 48 and 72 h after treatment, bioluminescent imaging is performed after i.p. injection of mice with 150 mg/kg of D-luciferin substrate. Sanguinarine treatment induces an obvious increase of luminescent signal as early as 48 h after initial treatment. A sustained bioluminescent imaging (BLI) intensity increased is observed throughout the course of experiment. At 72 h after treatment, the tumors are collected and subjected to TUNEL staining for evaluating apoptosis. Compared with the control tumors, the group treated with Sanguinarine exhibits significantly more cell apoptosis, indicated by the increased green signals from the sporadic apoptotic cells.
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    Egr-1| VEGFR
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    5578-73-4
  • Formula Weight
    367.78
  • Molecular Formula
    C20H14ClNO4
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    [Cl-].C[N+]1=C2C3=CC4=C(OCO4)C=C3C=CC2=C2C=CC3=C(OCO3)C2=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Han MH, et al.Toxicol Lett. 2013 Jul 4;220(2):157-66.
molnova catalog
related products
  • OBX02-011

    OBX02-011 is an effective and reversible inhibitor of EGFR tyrosine kinase with IC50s of 0.134 and 2.09 nM for triple mutants Del19/T790M/C797S and L858R/T790M/C797S.

  • AZ7550 hydrochloride

    AZ7550 hydrochloride, an active metabolite of AZD9291, inhibits the activity of IGF1R (IC50: 1.6 μM).

  • BPR1J-097

    BPR1J-097 is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM).